Sildenafil Citrate Tablet
Product Images NDC 72789-406

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 72789-406). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72789406 Label (72789406)

This packaging label is for Sildenafil Citrate USP 100 mg oral tablets, supplied by PD-Rx Pharmaceuticals, Inc. It shows a bottle label for a package of 30 tablets. The label includes the NDC number 72789-406-30, lot number H24A14, and expiration date 10/2025. Directions for use and warnings are partially visible in English and Spanish, emphasizing prescription-only status and storage instructions.*

FDA Label Image

Sildenafil-citrate-figure-1 (Sildenafil Citrate Figure 1)

A line graph showing mean change from baseline in sitting systolic blood pressure over 24 hours in healthy volunteers, comparing Sildenafil Citrate 100 mg with placebo. The x-axis represents time post dose in hours, and the y-axis shows systolic blood pressure change in mmHg. Two lines depict trends for the drug and placebo groups.*

FDA Label Image

Sildenafil-citrate-figure-2 (Sildenafil Citrate Figure 2)

A line chart titled 'Mean Standing Systolic Blood Pressure Change from Baseline' showing two data series: one for Doxazosin + Placebo (blue circles) and one for Doxazosin + Sildenafil 25 mg (black diamonds) over time postdose (0 to 8 hours). The y-axis shows change in systolic blood pressure in mmHg, and the x-axis shows time in hours.*

FDA Label Image

Sildenafil-citrate-figure-3 (Sildenafil Citrate Figure 3)

A line graph showing mean standing systolic blood pressure change from baseline over time postdose (in hours). Two data series are plotted: Doxazosin + Placebo (blue line with circles) and Doxazosin + Sildenafil 50 mg (black line with diamonds). The y-axis represents change in systolic blood pressure (mmHg), and the x-axis represents time in hours up to 8 hours postdose.*

FDA Label Image

Sildenafil-citrate-figure-4 (Sildenafil Citrate Figure 4)

Line graph showing mean standing systolic blood pressure change from baseline over 8 hours after dosing. The graph compares two groups: one receiving Doxazosin with Sildenafil 100 mg and another receiving Doxazosin with placebo. Blood pressure change is measured in mmHg, with time after dosing on the x-axis (hours) and pressure change on the y-axis.*

FDA Label Image

Sildenafil-citrate-figure-5 (Sildenafil Citrate Figure 5)

A line graph titled 'Mean Sildenafil Plasma Concentrations in Healthy Male Volunteers' depicting plasma concentration (ng/mL) of sildenafil over time (hours) after oral administration of either the test or commercial tablet. The graph shows a rapid increase to peak concentration around 1 hour followed by a gradual decline over 24 hours.*

FDA Label Image

Sildenafil-citrate-figure-6 (Sildenafil Citrate Figure 6)

Two bar graphs showing the effect on maintenance of erection by baseline score. The top graph illustrates the effect of sildenafil citrate, and the bottom graph shows the effect of placebo. Both graphs display percentages of patients at endpoint across baseline scores from 0 to 5, with bars segmented by scores 0 to 5 in the legend.*

FDA Label Image

Sildenafil-citrate-figure-7 (Sildenafil Citrate Figure 7)

Bar chart displaying the percentage of patients reporting improvement across different treatment groups including placebo, Sildenafil citrate 25 mg, 50 mg, and 100 mg. The vertical axis shows percentage improvement from 0 to 100%. The horizontal axis indicates treatment groups with patient sample sizes shown below each bar.*

FDA Label Image

Sildenafil-citrate-structure (Sildenafil Citrate Structure)

Chemical structure of sildenafil citrate showing its molecular framework, including heterocyclic rings, functional groups, and citrate moiety, consistent with the active ingredient sildenafil citrate in the product.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.